在固体器官移植接收者中,SARS-CoV-2尖端密码突变和抗尖端单克隆抗体治疗后住院的风险

Zachary A Yetmar1, Joseph D Yao2, Raymund R Razonable1,3

  • 1Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

PubMed
概括

针对COVID-19的单克隆抗体 (mAb) 治疗是有效的,但SARS-CoV-2变种可以发展突变突变,降低抗体易感性. 这些突变并没有预测mAbs.治疗的移植患者的住院治疗.